5. Actos - Top 10 Warnings and Recalls

Drug: Actos

2006 sales: $3.05 billion

Manufacturer: Takeda

Safety concern: “black box;” heart failure

Related Articles:
> Takeda touts Actos as heart attack-free. Report
> Actos on a good-news roll. Report
> Actos study points to reduction in heart attacks, strokes. Report
> Diabetes drug helps reduce rate of strokes. Report
> Avandia, Actos don't boost death risk. Report

5. Actos - Top 10 Warnings and Recalls

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.